The U.S. Food and Drug Administration (FDA) announced a label revision for metformin hydrochloride, effective June 30, 2025, to include a new boxed warning. This warning highlights the serious risk of lactic acidosis associated with metformin, which has been linked to severe outcomes including death.
Background
Metformin hydrochloride is a widely prescribed medication. The addition of a boxed warning reflects the FDA's assessment of postmarketing safety data related to its use.
Details of the Boxed Warning
The new boxed warning for metformin hydrochloride explicitly states: "WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp". This warning underscores the severe and potentially fatal nature of this adverse event, highlighting specific clinical manifestations that healthcare providers should recognize. The emphasis on the subtle onset further stresses the need for vigilance.
What this means
The implementation of this boxed warning on the metformin hydrochloride label is a significant update for patient safety. It serves as a critical reminder for healthcare professionals to consider the risk of lactic acidosis in patients receiving metformin, particularly when presenting with non-specific symptoms. Early diagnosis and prompt management are crucial given the severe outcomes associated with this condition. This label revision aims to enhance clinician awareness and guide appropriate risk assessment and patient counseling.
Source
This information is based on an FDA label revision for metformin hydrochloride, effective June 30, 2025. The details are available via the DailyMed database hosted by the National Library of Medicine at dailymed.nlm.nih.gov.